Evaluation of Small Vessel Disease by 3D-rotational Angiography

Around 68 patients who have acute cerebral ischemic symptoms attributed by cSVD will be recruited. Stroke etiology will be determined by Neurologists based on clinical syndrome, vascular imaging features and concurrent cardiovascular risks. The time window for recruitment is 4 weeks from the qualifying stroke.

After an informed consent for the study, potential candidates will undergo a cranial MRI and MR angiography. Patients who are found to have acute or subacute lacunar infarcts (defined as an infarct diameter < 15mm) in the territories supplied by the lateral lenticulostriate arteries, i.e. internal capsule, putamen, external capsular or corona radiata, will proceed to a 3-Dimensional rotational angiography (3DRA) at baseline and in 12 months. All recruited patients will receive single antiplatelet agents and statin. Their cognition, mobility and treat cardiovascular risk factors based on 4 pre-specified goals (as elaborated in Study Procedures) will also be regularly reviewed.

Inclusion criteria

• Patient is Chinese ONLY
• Patient is 30 to 85 years of age, inclusive.
• Patients who have an acute lacunar infarct in diffusion-weighted MRI compatible with small vessel disease in territories supplied by the lateral lenticulostriate arteries without relevant intracranial atherosclerotic stenosis ≥60%.
• Patient who has no contra-indication for the proposed imaging tests.
• Patient who understands the purpose and requirements of the study, and has an informed consent.
• Patient who has Modified Functional Ambulation Classification 4 or above.

Exclusion criteria

• Stroke etiology uncertain or unrelated to small vessel disease, such as cardioembolism, Moyamoya disease, ICAD or primary angiitis of CNS.
• Bleeding propensity: active peptic ulcer disease, major systemic hemorrhage within 30 days, thrombocytopenia (platelets <100 x 109/L), coagulopathy (INR >1.5).
• A medical condition that would not allow the patient to adhere to the protocol or complete the study.
• Patients with severe renal impairment.
• Patients who are taking warfarin and non-vitamin K antagonist oral anticoagulants would also be excluded.